Hospital Group Demands Federal Probe of 340B Rebates
- Facing concerns about access to affordable medications, several hospital associations are urging the Department of Health and human Services (HHS) to reconsider its proposed changes to the 340B...
- The 340B program, established in 1992, requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations - such as hospitals serving low-income patients - at significantly reduced...
- In an effort to address concerns about drug pricing and access, HHS proposed a new 340B rebate model in August 2024.
“`html
Hospital Groups Push Back Against HHS 340B Rebate Model
Table of Contents
Facing concerns about access to affordable medications, several hospital associations are urging the Department of Health and human Services (HHS) to reconsider its proposed changes to the 340B drug pricing program. The new model, intended to offer manufacturers alternative discount options, has sparked opposition due to its potential impact on vulnerable patients and safety-net providers.
What is the 340B Program?
The 340B program, established in 1992, requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations - such as hospitals serving low-income patients – at significantly reduced prices.These savings are intended to allow providers to stretch scarce resources and offer affordable medications to vulnerable populations. The program is a critical financial lifeline for many safety-net hospitals.
The Proposed Rebate Model and Concerns
In an effort to address concerns about drug pricing and access, HHS proposed a new 340B rebate model in August 2024. This model would allow manufacturers to offer alternative discounts, potentially shifting the financial burden from manufacturers to providers. However, hospital groups, including the American hospital Association (AHA), America’s Essential Hospitals, and the American Society of health-System Pharmacists, quickly voiced their concerns.
On August 8, 2024, these groups issued a letter requesting an extension of key deadlines, citing the speed and scope of the rollout as problematic. They argue the changes could destabilize safety-net providers and jeopardize access to care for millions of patients.
The American Medical Group Association (AMGA) also opposed the model, stating it would undermine the program’s original intent. Jerry Penso, MD, president and CEO of AMGA, explained in a September 8, 2024, letter that the pilot program would threaten access to affordable medications for patients due to the razor-thin margins on which safety-net providers operate. He urged HHS to withdraw the proposal and strengthen the existing upfront discount model.
Key Arguments Against the New Model
- Financial Instability: Safety-net hospitals operate on limited budgets and rely on 340B savings to provide care to vulnerable populations.
- Reduced Access to Care: Changes to the 340B program could force hospitals to reduce services or limit access to medications.
- Undermining Program Intent: Critics argue the new model shifts the focus from manufacturer discounts to complex rebate schemes, weakening the program’s core purpose.
- Administrative Burden: The proposed model introduces additional administrative complexities for providers.